QIONG MU ROSS: Open Payments
NPI 1053705673 · ADA, OK. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$806 in 60 payments from 10 companies in 2025. Trend: 2023 $569 · 2024 $560 · 2025 $806
Food & beverage: $806
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 23 | $226 |
| Supernus Pharmaceuticals, Inc. | 8 | $149 |
| Janssen Pharmaceuticals, Inc | 14 | $139 |
| Otsuka America Pharmaceutical, Inc. | 6 | $117 |
| Alkermes, Inc. | 4 | $80 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $24 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $21 |
| Novo Nordisk Inc | 1 | $19 |
| Lundbeck LLC | 1 | $17 |
| ABBVIE INC. | 1 | $14 |
Products named: FANAPT, Qelbree, INVEGA SUSTENNA, ABILIFY ASIMTUFII, REXULTI, ARISTADA, TRINTELLIX, CAPLYTA.
Industry payments across OK — which companies pay providers there.
